Literature DB >> 25962916

Importance of Real-Time Assays To Distinguish Multidrug Efflux Pump-Inhibiting and Outer Membrane-Destabilizing Activities in Escherichia coli.

Rajeev Misra1, Keith D Morrison2, Hyun Jae Cho3, Thanh Khuu3.   

Abstract

UNLABELLED: The constitutively expressed AcrAB multidrug efflux system of Escherichia coli shows a high degree of homology with the normally silent AcrEF system. Exposure of a strain with acrAB deleted to antibiotic selection pressure frequently leads to the insertion sequence-mediated activation of the homologous AcrEF system. In this study, we used strains constitutively expressing either AcrAB or AcrEF from their normal chromosomal locations to resolve a controversy about whether phenylalanylarginine β-naphthylamide (PAβN) inhibits the activities of AcrAB and AcrEF and/or acts synergistically with antibiotics by destabilizing the outer membrane permeability barrier. Real-time efflux assays allowed a clear distinction between the efflux pump-inhibiting activity of PAβN and the outer membrane-destabilizing action of polymyxin B nonapeptide (PMXBN). When added in equal amounts, PAβN, but not PMXBN, strongly inhibited the efflux activities of both AcrAB and AcrEF pumps. In contrast, when outer membrane destabilization was assessed by the nitrocefin hydrolysis assay, PMXBN exerted a much greater damaging effect than PAβN. Strong action of PAβN in inhibiting efflux activity compared to its weak action in destabilizing the outer membrane permeability barrier suggests that PAβN acts mainly by inhibiting efflux pumps. We concluded that at low concentrations, PAβN acts specifically as an inhibitor of both AcrAB and AcrEF efflux pumps; however, at high concentrations, PAβN in the efflux-proficient background not only inhibits efflux pump activity but also destabilizes the membrane. The effects of PAβN on membrane integrity are compounded in cells unable to extrude PAβN. IMPORTANCE: The increase in multidrug-resistant bacterial pathogens at an alarming rate has accelerated the need for implementation of better antimicrobial stewardship, discovery of new antibiotics, and deeper understanding of the mechanism of drug resistance. The work carried out in this study highlights the importance of employing real-time fluorescence-based assays in differentiating multidrug efflux-inhibitory and outer membrane-destabilizing activities of antibacterial compounds.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25962916      PMCID: PMC4518837          DOI: 10.1128/JB.02456-14

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  57 in total

1.  Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin.

Authors:  U S Eggert; N Ruiz; B V Falcone; A A Branstrom; R C Goldman; T J Silhavy; D Kahne
Journal:  Science       Date:  2001-08-23       Impact factor: 47.728

2.  Transition to the open state of the TolC periplasmic tunnel entrance.

Authors:  Christian Andersen; Eva Koronakis; Evert Bokma; Jeyanthy Eswaran; Daniel Humphreys; Colin Hughes; Vassilis Koronakis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

3.  Role of histone-like protein H-NS in multidrug resistance of Escherichia coli.

Authors:  Kunihiko Nishino; Akihito Yamaguchi
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

4.  Genetic evidence for functional interactions between TolC and AcrA proteins of a major antibiotic efflux pump of Escherichia coli.

Authors:  Henri Gerken; Rajeev Misra
Journal:  Mol Microbiol       Date:  2004-11       Impact factor: 3.501

Review 5.  Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

Authors:  Olga Lomovskaya; Keith A Bostian
Journal:  Biochem Pharmacol       Date:  2006-01-19       Impact factor: 5.858

6.  Overexpression of the multidrug efflux operon acrEF by insertional activation with IS1 or IS10 elements in Salmonella enterica serovar typhimurium DT204 acrB mutants selected with fluoroquinolones.

Authors:  Anne Olliver; Michel Vallé; Elisabeth Chaslus-Dancla; Axel Cloeckaert
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

7.  Dissection of β-barrel outer membrane protein assembly pathways through characterizing BamA POTRA 1 mutants of Escherichia coli.

Authors:  Drew Bennion; Emily S Charlson; Eric Coon; Rajeev Misra
Journal:  Mol Microbiol       Date:  2010-09       Impact factor: 3.501

8.  Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).

Authors:  Jürgen A Bohnert; Sabine Schuster; Eva Fähnrich; Rainer Trittler; Winfried V Kern
Journal:  J Antimicrob Chemother       Date:  2006-10-24       Impact factor: 5.790

9.  Analysis of a complete library of putative drug transporter genes in Escherichia coli.

Authors:  K Nishino; A Yamaguchi
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

10.  Conserved residues of the putative L6 loop of Escherichia coli BamA play a critical role in the assembly of β-barrel outer membrane proteins, including that of BamA itself.

Authors:  Margaret Leonard-Rivera; Rajeev Misra
Journal:  J Bacteriol       Date:  2012-06-29       Impact factor: 3.490

View more
  25 in total

1.  Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.

Authors:  Ketaki Soparkar; Alfred D Kinana; Jon W Weeks; Keith D Morrison; Hiroshi Nikaido; Rajeev Misra
Journal:  J Bacteriol       Date:  2015-08-03       Impact factor: 3.490

2.  Loss of Methyltransferase Function and Increased Efflux Activity Leads to Doxycycline Resistance in Burkholderia pseudomallei.

Authors:  Jessica R Webb; Erin P Price; Bart J Currie; Derek S Sarovich
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Clofazimine Reduces the Survival of Salmonella enterica in Macrophages and Mice.

Authors:  Toni A Nagy; Amy L Crooks; Joaquin L J Quintana; Corrella S Detweiler
Journal:  ACS Infect Dis       Date:  2020-04-29       Impact factor: 5.084

4.  A genetic platform to investigate the functions of bacterial drug efflux pumps.

Authors:  Tanisha Teelucksingh; Laura K Thompson; Shawna Zhu; Noah M Kuehfuss; James A Goetz; Stephanie E Gilbert; Craig R MacNair; Jennifer Geddes-McAlister; Eric D Brown; Georgina Cox
Journal:  Nat Chem Biol       Date:  2022-09-05       Impact factor: 16.174

5.  Colicin E1 opens its hinge to plug TolC.

Authors:  S Jimmy Budiardjo; Jacqueline J Stevens; Anna L Calkins; Ayotunde P Ikujuni; Virangika K Wimalasena; Emre Firlar; David A Case; Julie S Biteen; Jason T Kaelber; Joanna S G Slusky
Journal:  Elife       Date:  2022-02-24       Impact factor: 8.713

6.  Two Outer Membrane Proteins Contribute to Caulobacter crescentus Cellular Fitness by Preventing Intracellular S-Layer Protein Accumulation.

Authors:  K Wesley Overton; Dan M Park; Mimi C Yung; Alice C Dohnalkova; John Smit; Yongqin Jiao
Journal:  Appl Environ Microbiol       Date:  2016-09-23       Impact factor: 4.792

7.  Mutational Activation of Antibiotic-Resistant Mechanisms in the Absence of Major Drug Efflux Systems of Escherichia coli.

Authors:  Hyunjae Cho; Rajeev Misra
Journal:  J Bacteriol       Date:  2021-06-22       Impact factor: 3.490

Review 8.  The ins and outs of RND efflux pumps in Escherichia coli.

Authors:  João Anes; Matthew P McCusker; Séamus Fanning; Marta Martins
Journal:  Front Microbiol       Date:  2015-06-10       Impact factor: 5.640

9.  Development of a Potent Antimicrobial Peptide With Photodynamic Activity.

Authors:  Di Zhang; Jingyi Chen; Qian Jing; Zheng Chen; Azeem Ullah; Longguang Jiang; Ke Zheng; Cai Yuan; Mingdong Huang
Journal:  Front Microbiol       Date:  2021-06-01       Impact factor: 5.640

Review 10.  Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa.

Authors:  Jürg Dreier; Paolo Ruggerone
Journal:  Front Microbiol       Date:  2015-07-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.